Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

The Phase 3 Natron Study Evaluating Benralizumab in Patients with Hypereosinophilic Syndrome: Study Design and Patient Characteristics

Praveen Akuthota, Amy D Klion, Princess Ogbogu, Florence Roufosse, Paneez Khoury, Lila Bahadori, Gerben Bouma, Laura Brooks, Matthew Keith, Calvin N Ho, Priya Jain, Catherine J Datto

Blood (2023) 142 (Supplement 1): 1172.

https://doi.org/10.1182/blood-2023-179404

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype

Ashvind Anand Prabahran, Fernanda Gutierrez-Rodrigues, Serene Ahmad, Edward W Cowen, Ivana Darden, Emma M. Groarke, Marcela Ferrada, Peter C. Grayson, Amy D Klion, Katherine R. Calvo, Irina Maric, Neal S. Young, Bhavisha A. Patel

Blood (2022) 140 (Supplement 1): 2607–2608.

https://doi.org/10.1182/blood-2022-160287

Published: 2022

Journal Articles

A Noncoding Germline Variant Creates a Gain-of-Function De Novo Enhancer That up-Regulates IL5 Transcription to Cause Familial Hypereosinophilia, Revealing a Previously Undescribed Mechanism for Human Disease

Jung-Hyun Kim, Abbie Bowman, Senbagavalli Babu, Jan Cools, Sofie Demeyer, Majid Kazemian, Warren Leonard, Jian-Xin Lin, Michelle Makiya, Mathieu Perez, Colin L. Sweeney, Luis M Franco, Neelam Redekar, Justin Lack, Linda Resar, Amy D Klion

Blood (2022) 140 (Supplement 1): 1399–1400.

https://doi.org/10.1182/blood-2022-169953

Published: 2022

Journal Articles

Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration

So Gun Hong, Noriko Sato, Fanny Legrand, Manasi Gadkari, Michelle Makiya, Kindra Stokes, Katherine N. Howe, Shiqin Judy Yu, Nathaniel Seth Linde, Randall R. Clevenger, Timothy Hunt, Zonghui Hu, Peter L. Choyke, Cynthia E. Dunbar, Amy D. Klion, Luis M. Franco

Blood (2020) 136 (23): 2667–2678.

https://doi.org/10.1182/blood.2020005161

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Charcot-Leyden crystals: solving an enigma

Amy D. Klion

Blood (2018) 132 (20): 2111–2112.

https://doi.org/10.1182/blood-2018-09-873653

Published: 2018

Journal Articles

Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes

Sandhya R. Panch, Michael E. Bozik, Thomas Brown, Michelle Makiya, Calman Prussin, Donald G. Archibald, Gregory T. Hebrank, Mary Sullivan, Xiaoping Sun, Lauren Wetzler, JeanAnne Ware, Michael P. Fay, Cynthia E. Dunbar, Steven I. Dworetzky, Paneez Khoury, Irina Maric, Amy D. Klion

Blood (2018) 132 (5): 501–509.

https://doi.org/10.1182/blood-2018-02-835330

Published: 2018

Includes: Supplemental data

Journal Articles

Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea

Chi A. Ma, Liqiang Xi, Brian Cauff, Adam DeZure, Alexandra F. Freeman, Sophie Hambleton, Gary Kleiner, T. Ronan Leahy, Maureen O’Sullivan, Michelle Makiya, Grainne O’Regan, Stefania Pittaluga, Julie Niemela, Jennifer Stoddard, Sergio D. Rosenzweig, Mark Raffeld, Amy D. Klion, Joshua D. Milner

Blood (2017) 129 (5): 650–653.

https://doi.org/10.1182/blood-2016-09-737817

Published: 2017

Includes: Supplemental data

Journal Articles

Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study

Sandhya R. Panch, MD MPH, Michael Bozik, MD, Thomas Brown, RN, Ulrike Demarco, Dipl. Biol., Jamie Hahn, BS, Alexander Komarov, PhD, Tamika Magee, RN, Michelle Makiya, RN, Calman Prussin, MD, Armando Signore, PhD, Mary Sullivan, BA, Lauren Wetzler, MHS, PA, Cynthia E. Dunbar, MD, Steven Dworetzky, PhD, Irina Maric, MD, Amy D Klion, MD

Blood (2016) 128 (22): 1327.

https://doi.org/10.1182/blood.V128.22.1327.1327

Published: 2016

Journal Articles

How I treat hypereosinophilic syndromes

Amy D. Klion

Blood (2015) 126 (9): 1069–1077.

https://doi.org/10.1182/blood-2014-11-551614

Published: 2015

Includes: Supplemental data

Journal Articles

Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome

Amy D. Klion, Rojelio Mejia, Edward W. Cowen, Kennichi C. Dowdell, Kieron Dunleavy, Gary A. Fahle, Nicole Holland-Thomas, Irina Maric, Stefania Pittaluga, Mark Raffeld, Carlo Santos, Maryalice Stetler-Stevenson, Tammy Krogmann, Amber N. Shatzer, Siu-Ping Turk, Yuzhi Yin, Liqiang Xi, Calman Prussin, Jeffrey I. Cohen

Blood (2013) 121 (12): 2364–2366.

https://doi.org/10.1182/blood-2012-12-472720

Published: 2013

Journal Articles

How I treat hypereosinophilic syndromes

Amy D. Klion

Blood (2009) 114 (18): 3736–3741.

https://doi.org/10.1182/blood-2009-07-143552

Published: 2009

Journal Articles

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA -positive chronic eosinophilic leukemia: implications for optimal dosing

Amy D. Klion, Jamie Robyn, Irina Maric, Weiming Fu, Laura Schmid, Steven Lemery, Pierre Noel, Melissa A. Law, Marilyn Hartsell, Cheryl Talar-Williams, Michael P. Fay, Cynthia E. Dunbar, Thomas B. Nutman

Blood (2007) 110 (10): 3552–3556.

https://doi.org/10.1182/blood-2007-07-100164

Published: 2007

Journal Articles

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Todd M. Wilson, Irina Maric, Amy D. Klion, Cem Akin, Melody Carter, Weiming Fu, Jennifer Stoddard, Linda Scott, Arnold Kirshenbaum, Michael Fay, Thomas B. Nutman, Pierre Noel, Dean D. Metcalfe, Jamie Robyn

Blood (2006) 108 (11): 2683.

https://doi.org/10.1182/blood.V108.11.2683.2683

Published: 2006

Journal Articles

Safety and Tolerability of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Amy D. Klion, MD, Marc E. Rothenberg, MD, PhD, John J. Murray, MD,PhD, Anish Singh, MD, PhD, Hans-Uwe Simon, MD,PhD

Blood (2006) 108 (11): 2694.

https://doi.org/10.1182/blood.V108.11.2694.2694

Published: 2006

Journal Articles

Lineage Analysis of the FIPL1-PDGFRα Fusion Gene in Myeloproliferative Hypereosinophilic Syndrome.

Steven J. Lemery, MD, Jamie A. Robyn, MD/PhD, J. Philip McCoy, PhD, Joseph Kubofcik, BS, YaeJean Kim, MD, Thomas B. Nutman, MD, Cynthia E. Dunbar, MD, Amy D. Klion, MD

Blood (2004) 104 (11): 2441.

https://doi.org/10.1182/blood.V104.11.2441.2441

Published: 2004

Journal Articles

The etiology of severe anemia in a village and a periurban area in Mali

Alassane Dicko, Amy D. Klion, Mahamadou A. Théra, Issaka Sagara, Daniel Yalcouyé, Mohamed B. Niambele, Moussa Sogoba, Guimogo Dolo, Adama Dao, Dapa A. Diallo, Ogobara K. Doumbo, Louis H. Miller

Blood (2004) 104 (4): 1198–1200.

https://doi.org/10.1182/blood-2003-11-3884

Published: 2004

Journal Articles

Familial eosinophilia: a benign disorder?

Amy D. Klion, Melissa A. Law, William Riemenschneider, Mary Lou McMaster, Margaret R. Brown, McDonald Horne, Barbara Karp, Michael Robinson, Vandana Sachdev, Eben Tucker, Maria Turner, Thomas B. Nutman

Blood (2004) 103 (11): 4050–4055.

https://doi.org/10.1182/blood-2003-11-3850

Published: 2004

Journal Articles

Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

Amy D. Klion, Melissa A. Law, Pierre Noel, Yae-Jean Kim, Thomas P. Haverty, Thomas B. Nutman

Blood (2004) 103 (8): 2939–2941.

https://doi.org/10.1182/blood-2003-10-3620

Published: 2004

Journal Articles

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

Amy D. Klion, Jamie Robyn, Cem Akin, Pierre Noel, Margaret Brown, Melissa Law, Dean D. Metcalfe, Cynthia Dunbar, Thomas B. Nutman

Blood (2004) 103 (2): 473–478.

https://doi.org/10.1182/blood-2003-08-2798

Published: 2004

NARROW

The Phase 3 Natron Study Evaluating Benralizumab in Patients with Hypereosinophilic Syndrome: Study Design and Patient Characteristics

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype

A Noncoding Germline Variant Creates a Gain-of-Function De Novo Enhancer That up-Regulates IL5 Transcription to Cause Familial Hypereosinophilia, Revealing a Previously Undescribed Mechanism for Human Disease

Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration

Charcot-Leyden crystals: solving an enigma

Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes

Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea

Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study

How I treat hypereosinophilic syndromes

Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome

How I treat hypereosinophilic syndromes

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA -positive chronic eosinophilic leukemia: implications for optimal dosing

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Safety and Tolerability of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Lineage Analysis of the FIPL1-PDGFRα Fusion Gene in Myeloproliferative Hypereosinophilic Syndrome.

The etiology of severe anemia in a village and a periurban area in Mali

Familial eosinophilia: a benign disorder?

Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only